US approval of Brintellix first for Lundbeck/Takeda alliance
This article was originally published in Scrip
Executive Summary
The US FDA has granted the first approval worldwide to Lundbeck's Brintellix (vortioxetine) as a treatment for adults with major depressive disorder, paving the way for the multi-modal therapy to become the first commercial product under the Danish firm's strategic alliance with Takeda.
You may also be interested in...
Asia Deal Watch: RAPT And Hanmi Partner On CCR4 Antagonist Offering Potential In Multiple Cancer Types
RAPT can earn up to $108m in milestones plus sales royalties under the deal. BerGenBio, Piramal partner on developing AML therapy.
Daiichi’s EZH Contender Moves Ahead In Leukemia/Lymphoma
Japanese company starts pivotal trial with novel molecule as it looks to build oncology presence.
Gene And Cell Therapies In Asia: Pricing, Manufacturing Stand-Out Issues in Supportive Japan Ecosystem
The Japanese environment for cell and gene therapies and regenerative medicine in general continues to be highly supportive. But will pricing pressures under the NHI scheme move to the fore as more expensive products come to market?
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: